NEW HAVEN, Conn. — March 5, 2026 — Leads & Copy — Invivyd, Inc. (Nasdaq: IVVD) has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer, according to a recent announcement.
Dr. Mina, a former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women’s Hospital, is expected to bolster Invivyd’s medical leadership.
Marc Elia, Chairman of the Invivyd Board of Directors, stated that Dr. Mina’s skills, which encompass medical training, epidemiology, and basic immunology, will help accelerate the company’s work as it expands its pipeline of monoclonal antibodies.
Dr. Mina’s research background includes a focus on antibodies, vaccines, and infectious diseases, with expertise in COVID-19 and measles. His work has resulted in over 100 scientific publications and 10,000 citations. He also advised the U.S. federal and international governments on testing policies during the COVID pandemic and advocated for a shift in public health strategy. He also helped lead the U.S. government’s Home Test-to-Treat Program.
Dr. Mina has also served as chief science or chief medical officer at several diagnostics and digital health companies. Furthermore, his work identified aspects of the pathology of measles virus, including the discovery of “immune amnesia.” His research has also explored the body’s response to influenza and other vaccines.
Dr. Mina commented on Invivyd’s position in advancing infectious disease prevention through monoclonal antibodies. He sees potential for medical value creation and the advancement of standards of care in the prevention and treatment of viral diseases.
Invivyd, Inc. is a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, starting with SARS-CoV-2. The company utilizes a technology platform to develop antibodies.
In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb).
Source: Invivyd, Inc.
